Characterising the safety profile of lurasidone in clinical practice: A drug utilisation and safety study using a United Kingdom primary care database.

Date of Approval
Application Number
Technical Summary

The overall study aim is to characterise the safety profile of lurasidone in UK primary care in comparison to other second generation antipsychotics (SGAs) through a descriptive drug utilisation study (DUS) and a comparative longitudinal post-authorisation safety study (PASS). The DUS will assess initiation of prescribing of lurasidone versus SGAs, and characterise patients with respect to demographics, comorbidities, comedications, and off-label prescribing. The PASS will assess incidence rates and rate ratios for safety outcomes in patients who are prescribed lurasidone versus other SGAs. Safety outcomes will include: mortality, extrapyramidal symptoms, angioedema, neuroleptic malignant syndrome, suicidality, cardiac disease, cerebrovascular accident, increased serum creatinine, renal impairment/failure, metabolic effects (hyperglycaemia, weight gain, dyslipidemia), rhabdomyolysis, agranulocytosis, and seizure. Subgroup analyses will be conducted in both components in the following sub-populations: patients with renal and hepatic impairment, the elderly, patients with cardiac impairment, those co-prescribed strong CYP3A inhibitors/inducers, and children/adolescents. Exploratory analyses will be conducted on exposure to SGAs in pregnant women. The safety of lurasidone with other antipsychotics will be also be assessed. Asthenia, as a safety outcome in the elderly as well as dose in the elderly will be studied.


Andrew Maguire - Chief Investigator - OXON Epidemiology - Spain
Shreya Davé - Corresponding Applicant - Takeda Pharmaceuticals Company Ltd
Michelle Johnson - Collaborator - Roche
Shuk-Li Collings - Collaborator - Pfizer Ltd - UK


HES Admitted Patient Care;ONS Death Registration Data;Patient Level Townsend Score